SG10202009886SA - Methods for inhibiting angiogenesis in a subject in need thereof - Google Patents
Methods for inhibiting angiogenesis in a subject in need thereofInfo
- Publication number
- SG10202009886SA SG10202009886SA SG10202009886SA SG10202009886SA SG10202009886SA SG 10202009886S A SG10202009886S A SG 10202009886SA SG 10202009886S A SG10202009886S A SG 10202009886SA SG 10202009886S A SG10202009886S A SG 10202009886SA SG 10202009886S A SG10202009886S A SG 10202009886SA
- Authority
- SG
- Singapore
- Prior art keywords
- subject
- methods
- need
- inhibiting angiogenesis
- angiogenesis
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315857P | 2016-03-31 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202009886SA true SG10202009886SA (en) | 2020-11-27 |
Family
ID=59959191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009886SA SG10202009886SA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
| SG11201808242UA SG11201808242UA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808242UA SG11201808242UA (en) | 2016-03-31 | 2017-03-31 | Methods for inhibiting angiogenesis in a subject in need thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10870708B2 (en) |
| EP (1) | EP3436072A4 (en) |
| JP (3) | JP6865767B2 (en) |
| KR (3) | KR20230019991A (en) |
| CN (3) | CN109152834A (en) |
| AU (2) | AU2017240129B2 (en) |
| BR (1) | BR112018069732A2 (en) |
| CA (2) | CA3018774C (en) |
| CL (1) | CL2018002708A1 (en) |
| EA (2) | EA201892218A1 (en) |
| GE (1) | GEP20237466B (en) |
| IL (2) | IL305200A (en) |
| MA (1) | MA44518A (en) |
| MX (2) | MX2018011648A (en) |
| MY (1) | MY195432A (en) |
| NZ (1) | NZ745531A (en) |
| PH (1) | PH12018502046A1 (en) |
| SG (2) | SG10202009886SA (en) |
| WO (1) | WO2017173290A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170170B1 (en) | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
| CN107661492A (en) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | VEGF B new application |
| CN107537026A (en) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | VEGF B application |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| US11433276B2 (en) | 2019-05-10 | 2022-09-06 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength |
| US11957956B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies, Inc. | System, method and apparatus for rehabilitation and exercise |
| US11957960B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies Inc. | Method and system for using artificial intelligence to adjust pedal resistance |
| US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
| US11896540B2 (en) | 2019-06-24 | 2024-02-13 | Rehab2Fit Technologies, Inc. | Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy |
| US11071597B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Telemedicine for orthopedic treatment |
| US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
| US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
| US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
| US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
| US11101028B2 (en) | 2019-10-03 | 2021-08-24 | Rom Technologies, Inc. | Method and system using artificial intelligence to monitor user characteristics during a telemedicine session |
| US11075000B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Method and system for using virtual avatars associated with medical professionals during exercise sessions |
| US11955221B2 (en) * | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
| US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
| US11069436B2 (en) | 2019-10-03 | 2021-07-20 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks |
| KR20220110530A (en) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | MASP-2 Inhibitors and Methods of Use |
| EP4069238A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| BR112022010881A2 (en) | 2019-12-04 | 2022-08-23 | Omeros Corp | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT A DISEASE OR DISORDER ASSOCIATED WITH SERINE PROTEASE-2 ASSOCIATED WITH MANAN-BINDING LECTIN |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| KR20220031412A (en) | 2020-09-04 | 2022-03-11 | 주식회사 엘지에너지솔루션 | Apparatus and method for managing battery |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP3046318B2 (en) | 1987-12-15 | 2000-05-29 | ジーン・シアーズ・ピーティーワイ・リミテッド | Ribozyme |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| ATE149841T1 (en) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | VACCINES AGAINST CANCER AND INFECTIOUS DISEASES |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6969601B2 (en) * | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
| ES2629344T3 (en) | 2003-05-12 | 2017-08-08 | Helion Biotech Aps | Antibodies against MASP-2 |
| US20130266559A1 (en) * | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US11130801B2 (en) * | 2011-01-13 | 2021-09-28 | Case Western Reserve University | Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies |
| ES2683307T3 (en) * | 2011-04-08 | 2018-09-26 | University Of Leicester | Methods to treat conditions associated with MASP-2-dependent complement activation |
| MX347691B (en) * | 2011-05-04 | 2017-05-09 | Omeros Corp | Compositions for inhibiting masp-2 dependent complement acitivation. |
| EP2723361B1 (en) * | 2011-06-22 | 2019-10-30 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| CA3214532A1 (en) * | 2012-06-18 | 2013-12-27 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| CN105683219B (en) * | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | Methods for treating conditions associated with MASP-2 dependent complement activation |
-
2017
- 2017-03-31 CA CA3018774A patent/CA3018774C/en active Active
- 2017-03-31 SG SG10202009886SA patent/SG10202009886SA/en unknown
- 2017-03-31 WO PCT/US2017/025411 patent/WO2017173290A1/en active Application Filing
- 2017-03-31 CN CN201780021420.XA patent/CN109152834A/en active Pending
- 2017-03-31 KR KR1020237002512A patent/KR20230019991A/en not_active Application Discontinuation
- 2017-03-31 CA CA3096270A patent/CA3096270A1/en active Pending
- 2017-03-31 KR KR1020187030563A patent/KR20180128941A/en not_active IP Right Cessation
- 2017-03-31 BR BR112018069732A patent/BR112018069732A2/en unknown
- 2017-03-31 NZ NZ745531A patent/NZ745531A/en unknown
- 2017-03-31 CN CN202210704608.7A patent/CN115137816A/en active Pending
- 2017-03-31 EA EA201892218A patent/EA201892218A1/en unknown
- 2017-03-31 IL IL305200A patent/IL305200A/en unknown
- 2017-03-31 CN CN202311390678.0A patent/CN117582494A/en active Pending
- 2017-03-31 MA MA044518A patent/MA44518A/en unknown
- 2017-03-31 JP JP2018551413A patent/JP6865767B2/en active Active
- 2017-03-31 MX MX2018011648A patent/MX2018011648A/en unknown
- 2017-03-31 IL IL262021A patent/IL262021B2/en unknown
- 2017-03-31 MY MYPI2018001577A patent/MY195432A/en unknown
- 2017-03-31 KR KR1020207027488A patent/KR20200113290A/en not_active Application Discontinuation
- 2017-03-31 SG SG11201808242UA patent/SG11201808242UA/en unknown
- 2017-03-31 EA EA202191185A patent/EA202191185A1/en unknown
- 2017-03-31 AU AU2017240129A patent/AU2017240129B2/en active Active
- 2017-03-31 GE GEAP201714913A patent/GEP20237466B/en unknown
- 2017-03-31 US US15/476,154 patent/US10870708B2/en active Active
- 2017-03-31 EP EP17776787.8A patent/EP3436072A4/en active Pending
-
2018
- 2018-09-24 MX MX2022012380A patent/MX2022012380A/en unknown
- 2018-09-24 PH PH12018502046A patent/PH12018502046A1/en unknown
- 2018-09-25 CL CL2018002708A patent/CL2018002708A1/en unknown
-
2020
- 2020-03-05 AU AU2020201633A patent/AU2020201633B2/en active Active
- 2020-04-22 JP JP2020075784A patent/JP2020125332A/en active Pending
- 2020-11-17 US US16/950,645 patent/US20210189009A1/en active Pending
-
2022
- 2022-05-27 JP JP2022086774A patent/JP2022110159A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202009886SA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| ZA201805238B (en) | Methods for inhibiting fibrosis in a subject in need thereof | |
| GB2552084B (en) | A locker system | |
| GB201522666D0 (en) | Feature extraction | |
| HK1214981A1 (en) | A micro-humidifier | |
| IL249868A0 (en) | A method | |
| GB201405566D0 (en) | A locker system | |
| GB201509864D0 (en) | A beverage | |
| PT3107946T (en) | A polyiso-urea | |
| GB201415098D0 (en) | A garment | |
| HRP20201981T8 (en) | A method for smoltification in salmonidae | |
| GB201416742D0 (en) | A locker system | |
| GB2540064B (en) | Barrier for a bed | |
| GB201411043D0 (en) | A locker system | |
| PL3271447T3 (en) | A brewing method | |
| GB201402247D0 (en) | A footgauge | |
| GB2542843B (en) | Inductive position detector | |
| HK1200644A2 (en) | A horizontal rain-proofing device | |
| GB2531658B (en) | A barrier means | |
| ZA201600761B (en) | A tie | |
| AU201517057S (en) | A top | |
| GB2524135B (en) | A locker system | |
| AU359395S (en) | A coffee machine | |
| GB201420788D0 (en) | A sled device | |
| GB201417947D0 (en) | A beverage |